2026-10-29 20:11:45 UTC#540475newconfirmedpress release
DFTX stock news
DFTX stock news. Deduplicated factual headlines, scored for importance, with entity sentiment and the sectors, countries, and asset classes affected. Updates open into the storyline.
See the full wire20 wire items
2026-10-09 19:21:00 UTC#440241newconfirmednews
JPMorgan initiates coverage of Definium Therapeutics (DFTX) at Overweight
2026-09-15 14:25:00 UTC#314574newconfirmednews
Canaccord Genuity maintains Buy rating on Definium Therapeutics (DFTX)
dow_jonesimportance 0.30trust 0.70Definium Therapeutics, Inc. +0.20Canaccord Genuity Group Inc. +0.20
2026-09-15 13:00:00 UTC#313980newconfirmednews
Baird maintains Outperform on Definium Therapeutics (DFTX), raises price target to $79 from $75
dow_jonesimportance 0.30trust 0.70Definium Therapeutics, Inc. +0.40Robert W. Baird & Co. Incorporated +0.40
2026-09-14 15:53:00 UTC#308559duplicateconfirmednews
Definium Therapeutics reports positive Phase 3 trial data for DT120 LSD-based anxiety drug
2026-09-14 15:05:00 UTC#308278newconfirmednews
H.C. Wainwright & Co. maintains $70.00 price target on Definium Therapeutics (DFTX)
2026-09-14 12:00:00 UTC#307030newconfirmednews
Needham maintains $66.00 price target on Definium Therapeutics (DFTX)
2026-09-14 11:55:27 UTC#306951duplicateconfirmednews
Definium Therapeutics shares rise as DT120 LSD-based anxiety drug succeeds in second late-stage trial
reutersimportance 0.40trust 0.80Definium Therapeutics, Inc. +0.80DT120 +0.80Food and Drug Administration +0.20+2 entities
2026-09-14 11:54:00 UTC#306958duplicateconfirmednews
Definium Therapeutics shares rise 18.7% following positive Phase 3 results for DT120 anxiety drug
dow_jonesimportance 0.40trust 0.80Definium Therapeutics +0.80DT120 +0.80Hamilton Anxiety Rating Scale 0
2026-09-14 11:15:41 UTC#306703duplicateconfirmedpress release
Definium Therapeutics reports positive Phase 3 Panorama study results for DT120 ODT in GAD
financial postimportance 0.60trust 0.90Definium Therapeutics, Inc. +0.80DT120 ODT +0.80Panorama +0.70+2 entities
2026-09-14 11:03:04 UTC#306688duplicateconfirmednews
Definium's LSD-based anxiety drug succeeds in second late-stage study, Reuters reports
2026-09-14 11:00:00 UTC#306644newconfirmednews
Definium's DT120 LSD-based anxiety drug succeeds in second late-stage trial, reducing symptoms by 9.8 points
reutersimportance 0.70trust 0.90Definium Therapeutics +0.80DT120 +0.80Robert Barrow +0.40+1 entities
2026-09-13 21:03:09 UTC#304276newconfirmedpress release
Definium Therapeutics to host webcast on September 14, 2026, to discuss Phase 3 Panorama study results in GAD
2026-09-11 13:58:00 UTC#299090newconfirmednews
RBC Capital maintains $66.00 price target on Definium Therapeutics (DFTX)
2026-09-10 11:08:01 UTC#291381newconfirmedpress release
Definium Therapeutics to present Phase 3 Emerge and Voyage trial data at Psych Congress 2026
2026-09-08 12:03:01 UTC#280419duplicateconfirmednews
Definium Therapeutics DT120 ODT Receives FDA Breakthrough Therapy Designation for MDD
tradingviewimportance 0.30trust 0.80Definium Therapeutics +0.80DT120 +0.80Food and Drug Administration +0.60+2 entities
2026-09-08 11:06:56 UTC#280124newconfirmedpress release
Definium Therapeutics DT120 receives FDA Breakthrough Therapy designation for Major Depressive Disorder
financial postimportance 0.60trust 0.90Definium Therapeutics, Inc. +0.80DT120 +0.80Food and Drug Administration +0.70+2 entities
2026-08-18 09:17:00 UTC#188609newconfirmednews
B of A Securities initiates coverage of Definium Therapeutics (DFTX) with Buy rating
dow_jonesimportance 0.30trust 0.70Definium Therapeutics, Inc. +0.40Bank of America Corporation +0.40
2026-08-13 16:43:00 UTC#173250newconfirmednews
Canaccord Genuity maintains Buy rating on Definium Therapeutics (DFTX)
dow_jonesimportance 0.30trust 0.70Definium Therapeutics, Inc. +0.20Canaccord Genuity Group Inc. +0.20
2026-08-13 15:17:00 UTC#172734newconfirmednews